A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

Mean rates of colorectal cancer (CRC) screening tripled among average-risk individuals 45-49 years old after the U.S.

Home-based phototherapy for plaque and guttate psoriasis is as effective as office-based phototherapy, results of the ...

Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...